Your session is about to expire
← Back to Search
Diagnostic (fluciclovine F18 PET/CT) for Glioblastoma
N/A
Waitlist Available
Led By Jason M Johnson
Research Sponsored by M.D. Anderson Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 6 months
Awards & highlights
Study Summary
This trial studies how well PET/CT scanning with F18 fluciclovine can measure tumor size and response to radiation therapy in people with glioblastoma.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 6 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 6 months
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Tumor volume
Secondary outcome measures
Changes in F18 fluciclovine defined disease with surgery and radiation
Post-radiation enhancing brain tissue
Other outcome measures
Results from pathology
Trial Design
1Treatment groups
Experimental Treatment
Group I: Diagnostic (fluciclovine F18 PET/CT)Experimental Treatment3 Interventions
Patients receive fluciclovine F18 IV and undergo 4 PET/CT scans over 10 minutes paired with standard of care MRI within 14 days prior to initial maximal tumor resection, within 7 days prior to initiation of radiation therapy, 28 days after the completion of radiation therapy, and 6 months after the completion of radiation therapy.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Positron Emission Tomography
2008
Completed Phase 2
~2240
Computed Tomography
2017
Completed Phase 2
~2720
Find a Location
Who is running the clinical trial?
M.D. Anderson Cancer CenterLead Sponsor
2,971 Previous Clinical Trials
1,787,204 Total Patients Enrolled
42 Trials studying Glioblastoma
1,957 Patients Enrolled for Glioblastoma
National Cancer Institute (NCI)NIH
13,658 Previous Clinical Trials
40,924,477 Total Patients Enrolled
322 Trials studying Glioblastoma
23,103 Patients Enrolled for Glioblastoma
Jason M JohnsonPrincipal InvestigatorM.D. Anderson Cancer Center
6 Previous Clinical Trials
161 Total Patients Enrolled
1 Trials studying Glioblastoma
21 Patients Enrolled for Glioblastoma
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- You are currently expecting a baby.
Research Study Groups:
This trial has the following groups:- Group 1: Diagnostic (fluciclovine F18 PET/CT)
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
What is the anticipated enrollment size for this research endeavor?
"Affirmative. According to the information posted on clinicaltrials.gov, this research is actively recruiting patients who match its criteria. The original posting date was April 30th 2019 and it has most recently been modified on February 24th 2023. 25 participants are needed from 1 medical centre for proper data collection."
Answered by AI
Are there still available slots for participants in this clinical trial?
"According to the clinicaltrials.gov listing, this medical study is ongoing and actively searching for patients in need of treatment. This trial was initially inaugurated on April 30th 2019, with its latest update taking place February 24th 2023."
Answered by AI
Recent research and studies
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger